Treatment follow-up reveals positive results for MS patients

[MSUK]

Results from the BENEFIT11 trial has found that early treatment with IFNB-1b leads to improvements in cognition and fatigue in the long-term, as well as sustained employment and favourable magnetic resonance imaging (MRI) outcomes, measured at the 11-year mark, according to the study Long-Term Impact Of Early MS Treatment With Interferon Beta-1b: Clinical, MRI, Employment And Patient-Reported Outcomes (PROs) at the 11-Year Follow-up of BENEFIT (BENEFIT 11)...... Read More - http://www.ms-uk.org/betaferon